Kalaris Therapeutics reported cash from operations of -$11.03M and free cash flow of -$11.03M for the quarter ended Jun 2026, up 12.2% year over year. This cash flow statement covers 29 quarters of results from Jun 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Jun2019 | Sep2019 | Dec2019 | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||||||||||||||||
| Net Income | -45.51M | -56.93M | -43.86M | -44.69M | -42.07M | -38.09M | -41.91M | -45.27M | -44.27M | -59.70M | -1.40M | -3.33M | -37.17M | -7.06M | -11.80M | -12.26M | -12.74M | -10.80M | -11.83M | -12.39M | |||||||||
| Depreciation and Depletion | 0.01M | 0.01M | 0.01M | ||||||||||||||||||||||||||
| Share-based Compensation | 10.29M | 15.86M | 10.47M | 10.95M | 10.86M | 9.04M | 10.03M | 10.29M | 10.47M | 9.99M | 0.03M | 0.32M | 0.26M | 0.28M | 0.37M | 0.59M | 0.64M | 0.33M | 0.58M | 0.64M | |||||||||
| Change in Interest Receivables | -0.26M | -0.10M | 0.12M | -0.08M | 0.17M | -0.10M | 0.09M | -0.14M | 0.13M | -0.03M | -0.03M | -0.08M | -0.04M | -0.05M | |||||||||||||||
| Cash from Operations | -36.44M | -28.07M | -46.48M | -28.88M | -35.13M | -31.57M | -32.12M | -27.12M | -34.48M | -30.73M | -4.52M | -3.98M | -4.32M | -7.88M | -7.44M | -12.56M | -11.31M | -7.09M | -11.60M | -11.03M | |||||||||
| Depreciation, Depletion & Amortization | |||||||||||||||||||||||||||||
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.04M | 0.09M | 0.47M | 0.09M | 0.09M | 0.09M | 0.09M | 0.09M | 0.09M | 0.14M | 0.01M | 0.01M | 0.01M | ||||||||||||||||
| Change in Working Capital | |||||||||||||||||||||||||||||
| Change in Account Payables | -1.24M | -0.60M | 1.70M | -0.90M | 0.93M | 1.31M | -3.20M | 0.87M | -0.38M | 0.14M | |||||||||||||||||||
| Change in Accured Expenses | 2.09M | 11.48M | -13.79M | 3.42M | -0.52M | -1.74M | -0.49M | 5.39M | -1.86M | -5.56M | -0.28M | 0.06M | -0.33M | 0.67M | -0.01M | -0.80M | 1.22M | 1.73M | 0.12M | 0.75M | |||||||||
| Change in Taxes | -0.50M | -0.35M | -0.03M | 0.00M | -0.00M | -0.13M | |||||||||||||||||||||||
| Other Working Capital Changes | 3.58M | -0.70M | -0.28M | -1.14M | 3.29M | 1.17M | 0.33M | -3.19M | 0.22M | -2.98M | 0.40M | 0.01M | -0.33M | 0.73M | -1.42M | 2.01M | -2.04M | -0.36M | -0.04M | 1.08M | |||||||||
| Investing Activities | |||||||||||||||||||||||||||||
| Capital Expenditures | 0.03M | -0.37M | 0.02M | ||||||||||||||||||||||||||
| Cash from Investing Activities | 54.97M | -13.52M | -54.98M | -0.48M | -38.56M | 13.54M | 41.72M | 37.89M | -66.85M | 25.22M | 40.00M | 30.00M | 20.00M | 5.00M | 14.98M | -50.35M | 20.17M | ||||||||||||
| Financing Activities | |||||||||||||||||||||||||||||
| Debt Issuance and Repayment | |||||||||||||||||||||||||||||
| Long-Term Debt Issuances | 4.99M | 5.00M | 9.97M | 7.50M | |||||||||||||||||||||||||
| Change in Capital Stock | |||||||||||||||||||||||||||||
| Net Equity Issued and Repurchased | 0.07M | 126.18M | 1.59M | 0.07M | 0.01M | ||||||||||||||||||||||||
| Misc. | |||||||||||||||||||||||||||||
| Cash from Financing Activities | 0.07M | 126.42M | 0.29M | 0.01M | 6.58M | 4.98M | 0.00M | 7.58M | 107.27M | 47.74M | -1.70M | -0.38M | |||||||||||||||||
| Exchange Rate Effect | -0.10M | ||||||||||||||||||||||||||||
| Change in Cash | 18.59M | -41.53M | -101.45M | -29.11M | 52.74M | -17.74M | 9.61M | 81.26M | -101.33M | -5.51M | 2.06M | 1.01M | -4.33M | -0.27M | 99.83M | -12.54M | -46.04M | 55.67M | -63.63M | 8.75M | |||||||||
| Free Cash Flow | -36.47M | -27.70M | -46.48M | -28.88M | -35.13M | -31.57M | -32.12M | -27.12M | -34.48M | -30.73M | -4.52M | -3.98M | -4.32M | -7.88M | -7.44M | -12.56M | -11.31M | -7.10M | -11.60M | -11.03M | |||||||||
| Net Cash Flow | 18.53M | -41.53M | -101.45M | -29.36M | 52.74M | -17.74M | 9.61M | 10.77M | -101.33M | -5.51M | 42.06M | 31.00M | 15.68M | 4.70M | 99.83M | -12.56M | -11.31M | 55.64M | -63.65M | 8.77M |
Pull Kalaris Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=KLRS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "KLRS", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=KLRS&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();